<DOC>
	<DOCNO>NCT02280408</DOCNO>
	<brief_summary>Ebola virus infect killed people , mostly Africa . In 2014 , Ebola virus affect several thousand people . There approved effective way treat prevent Ebola . Researchers try develop vaccine . This study anti-Ebola vaccine VSV ZEBOV ( BPSC-1001 ) see safe see affect people 's immune system .</brief_summary>
	<brief_title>Safety Immunogenicity Prime-Boost Vesicular Stomatitis Virus ( VSV ) Ebola Vaccine Healthy Adults ( V920-002 )</brief_title>
	<detailed_description>Between 1994 present , many Ebola virus ( EBOV ) outbreaks affect mostly central Africa . However , 2014 West African outbreak significantly exceed previous outbreak geographic range , number individual affect disruption typical activity civil society . This Phase 1 safety tolerability study evaluate novel vaccine Ebola use live replicate vesicular stomatitis virus ( VSV ) replace gene encode G envelope glycoprotein gene encode envelope glycoprotein Zaire strain Ebola ( VSVΔG-ZEBOV also know BPSC-1001 ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA : Healthy male female , age 18 65 ( inclusive ) time screen Females childbearing potential male , must willing use effective method contraception , least 14 day prior vaccination Day 56 would include : Oral contraceptive , either combined progestogen alone injectable progestogen implant etonogestrel levonorgestrel oestrogenic vaginal ring percutaneous contraceptive patch intrauterine device intrauterine system male partner sterilization male condom combine spermicide Must willing minimize blood body fluid exposure others least 7 day vaccination , include : Use effective barrier prophylaxis , latex condom , sexual interaction ( regardless childbearing status sexual orientation ) Avoiding share needle , razor , eat utensil , drink cup , toothbrush Avoiding openmouth kissing Must willing forgo blood donation one year Must agree enroll another study investigational agent prior completion Day 56 participate investigational vaccine study last require protocol visit Day 365 Ability provide inform consent EXCLUSION CRITERIA : FACTORS THAT INCREASE RISK TO THE SUBJECT : Clinically significant medical condition , physical examination finding , clinically significant abnormal laboratory result , past medical history clinically significant implication current health . A clinically significant condition process include limit : A process would affect immune response A process would require medication affect immune response Any contraindication repeat injection blood draw A condition require active medical intervention monitoring avert grave danger participant health wellbeing study period A condition process sign symptom could confuse reaction vaccine Any condition specifically list among exclusion criterion Active malignancy Asplenia History GuillainBarré Syndrome History neurological neuropsychiatric disorder may either increase risk ( history encephalitis , narcolepsy , stroke , depression , bipolar disorder , seizure , etc . ) could interfere assessment safety ( e.g. , frequent headache ) History autoimmune disease History hemoglobinopathy coagulopathy Women breastfeed Positive urine serum pregnancy test Abnormal chemistry panel ; define : Defined Grade 3 great toxicity ( regardless clinical significance ) toxicity table Evaluating creatinine , alanine aminotransferase , aspartate aminotransferase , total bilirubin , estimate glomerular filtration rate Abnormal complete blood count ( CBC ) define : Defined Grade 3 great toxicity ( regardless clinical significance ) toxicity table Evaluating white blood cell ( WBC ) , hemoglobin , hematocrit , platelet Abnormal urinalysis define : Defined Grade 3 great toxicity ( regardless clinical significance ) toxicity table Evaluating red blood cell ( RBC ) , protein , glucose Positive serology hepatitis B surface antigen Positive serology hepatitis C Positive serology human immunodeficiency virus ( HIV ) Known allergy component VSVΔGZEBOV vaccine ( BPSC1001 ) vaccine product ( VSV , albumin , tris ) History severe local systemic reaction vaccination history severe allergic reaction FACTORS THAT MAY LIMIT VSB REPLICATION OR MAKE INTERPRETATION OF IMMUNOGENICITY DIFFICULT : History prior infection filovirus prior participation filovirus vaccine trial Veterinarian rancher expose livestock know infected VSV History prior infection VSV receipt VSV vectored vaccine FACTOR THAT WOULD INCREASE RISK TO OTHERS DUE TO VSB VIRAL SHEDDING : Is healthcare worker direct contact patient within 14 day vaccination Is animal care worker , direct contact animal ( livestock domestic , besides subject family pet ) within 14 day vaccination Has household contact ( HHC ) immunodeficient ( opinion investigator ) , pregnant , unstable medical condition , age 5 year Is childcare worker direct contact child 5 year age young FACTORS THAT COULD IMPAIR INTERPRETATION OR EXECUTION OF THE STUDY : Receipt investigational drug within 5 half live 30 day , whichever longer , prior study drug administration ( i.e. , Day 0 ) Receipt license vaccine 14 day plan study immunization Receipt immunoglobulins and/or blood product within 120 day precede study entry plan study period Immunosuppressive medication receive within 168 day first vaccination . ( Not include : [ 1 ] corticosteroid nasal spray allergic rhinitis ; [ 2 ] topical corticosteroid mild , uncomplicated dermatitis ; [ 3 ] oral/parenteral corticosteroid give nonchronic condition expect recur [ length therapy 10 day less completion least 30 day prior vaccination ( ) ] . ) Allergy treatment antigen injection within 30 day first vaccination schedule Day 56 Participants , judgment investigator , unlikely comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>